Table 2.

Statistical analysis of change from pre-dose in FEV₁ through 24 h post-dose compared with placebo group (ITT population); Least square mean difference from pre-dose FEV₁ (95% CI) all values P < 0.001; ^*P < 0.01; NS not significant. n = 37 for placebo, n values for each dose are stated in the table

Time	Dose (μg 0.5 ml–1)
	12.5 – placebo (n = 39)	50 – placebo (n = 38)	100 – placebo (n = 37)	200 – placebo (n = 37)	400 – placebo (n = 37)
5 min	0.06 (0.03–0.09)	0.08 (0.04–0.11)	0.10 (0.07–0.13)	0.13 (0.1–0.16)	0.14 (0.11–0.17)
15 min	0.10 (0.06–0.14)	0.15 (0.11–0.19)	0.17 (0.13–0.21)	0.21 (0.17–0.25)	0.21 (0.17–0.25)
30 min	0.10 (0.07–0.14)	0.17 (0.14–0.21)	0.21 (0.17–0.24)	0.22 (0.18–0.26)	0.23 (0.20–0.27)
1 h	0.13 (0.09–0.17)	0.20 (0.16–0.24)	0.21 (0.17–0.25)	0.23 (0.20–0.27)	0.23 (0.19–0.27)
2 h	0.13 (0.08–0.17)	0.20 (0.16–0.25)	0.21 (0.17–0.26)	0.24 (0.19–0.28)	0.22 (0.18–0.26)
4 h	0.07 (0.02–0.11)*	0.15 (0.10–0.19)	0.16 (0.12–0.21)	0.21 (0.16–0.26)	0.19 (0.15–0.24)
8 h	0.08 (0.03–0.12)	0.14 (0.10–0.18)	0.13 (0.09–0.18)	0.19 (0.15–0.24)	0.20 (0.15–0.24)
12 h	0.07 (0.02–0.11)*	0.15 (0.10–0.19)	0.12 (0.07–0.17)	0.19 (0.14–0.23)	0.17 (0.13–0.22)
24 h	0.04 (−0.01–0.08) NS	0.07 (0.03–0.11)	0.10 (0.06–0.14)	0.12 (0.08–0.16)	0.10 (0.06–0.14)